Humana (NYSE:HUM) Lowered to “Strong Sell” Rating by Zacks Research

Humana (NYSE:HUM) was downgraded by research analysts at Zacks Research from a “hold” rating to a “strong sell” rating in a research note issued on Tuesday,Zacks.com reports. Zacks Research also issued estimates for Humana’s Q1 2027 earnings at $8.98 EPS, Q2 2027 earnings at $6.34 EPS and Q3 2027 earnings at $0.70 EPS.

A number of other equities research analysts have also issued reports on the company. Jefferies Financial Group reduced their target price on Humana from $310.00 to $235.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Sanford C. Bernstein reissued an “outperform” rating and set a $344.00 price target on shares of Humana in a research note on Tuesday, January 6th. Oppenheimer set a $250.00 price target on Humana in a research note on Thursday, February 12th. Cantor Fitzgerald reduced their price target on Humana from $290.00 to $201.00 and set a “neutral” rating on the stock in a research note on Thursday, February 12th. Finally, Raymond James Financial reduced their price target on Humana from $340.00 to $230.00 and set an “outperform” rating on the stock in a research note on Friday, February 13th. Seven analysts have rated the stock with a Buy rating, fifteen have assigned a Hold rating and four have assigned a Sell rating to the stock. Based on data from MarketBeat.com, Humana presently has an average rating of “Hold” and a consensus target price of $222.09.

Humana Price Performance

HUM stock opened at $198.20 on Tuesday. Humana has a 1 year low of $163.11 and a 1 year high of $315.35. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.00 and a current ratio of 2.00. The stock’s 50 day moving average price is $180.95 and its 200 day moving average price is $231.53. The firm has a market cap of $23.79 billion, a P/E ratio of 20.18, a PEG ratio of 2.10 and a beta of 0.44.

Humana (NYSE:HUM) last posted its earnings results on Wednesday, February 11th. The insurance provider reported ($3.96) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($4.01) by $0.05. Humana had a return on equity of 11.43% and a net margin of 0.92%.The firm had revenue of $32.64 billion for the quarter, compared to analyst estimates of $32.08 billion. During the same quarter in the prior year, the company earned ($2.16) EPS. Humana’s revenue was up 11.3% on a year-over-year basis. Humana has set its FY 2026 guidance at 9.000-9.000 EPS. On average, sell-side analysts expect that Humana will post 16.47 earnings per share for the current fiscal year.

Insider Buying and Selling at Humana

In other Humana news, insider Sanjay K. Shetty purchased 810 shares of Humana stock in a transaction on Monday, February 23rd. The shares were bought at an average price of $185.21 per share, with a total value of $150,020.10. Following the purchase, the insider directly owned 11,657 shares in the company, valued at $2,158,992.97. This trade represents a 7.47% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 0.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Humana

Institutional investors have recently made changes to their positions in the stock. Montag A & Associates Inc. grew its stake in shares of Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock valued at $25,000 after buying an additional 94 shares during the period. CoreCap Advisors LLC grew its stake in shares of Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock valued at $27,000 after buying an additional 37 shares during the period. Fideuram Asset Management Ireland dac purchased a new stake in shares of Humana during the 4th quarter valued at $27,000. Reflection Asset Management purchased a new stake in shares of Humana during the 4th quarter valued at $29,000. Finally, Rosenberg Matthew Hamilton grew its stake in shares of Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock valued at $30,000 after buying an additional 68 shares during the period. 92.38% of the stock is owned by hedge funds and other institutional investors.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.